Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Accelerated drug development program for Oxi-104

Aug. 23, 1996

Antineoplastic agents from Japan Energy

Aug. 23, 1996

VIMRxyn to undergo phase I in glioma patients

Aug. 23, 1996

NeXstar describes ELONA and significance for VEGF inhibitor development

Aug. 23, 1996

Shionogi reports ras transformation inhibitor

Aug. 23, 1996

Farnesyl transferase inhibitors from Pierre Fabre

Aug. 23, 1996

Study indicates ISIS-3521/CGP-64128A inhibits tumor growth

Aug. 23, 1996

IDEC-Y2B8/IDEC-C2B8 combination undergoes phase I/II

Aug. 23, 1996

Fareston launched in the U.K.

Aug. 23, 1996

Phase I pharmacokinetic study of asulacrine initiated

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 17, 2025
Clinical trial fraud ends with guilty pleas
BioWorld
In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...